Article
Synthetic tumor‐specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease
17 Jun 2009
Abstract excerpt
BACKGROUND: Imatinib is the current standard frontline therapy for chronic myelogenous leukemia (CML). In the majority of patients, imatinib induces a complete cytogenetic response (CCyR); however, complete molecular responses are infrequent. The Bcr-Abl fusion creates a unique sequence of amino acids that could constitute a target for immunomodulation. METHODS: A mixture of heteroclitic and native peptides...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.